Investors Home

Company Profile

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney disease and acute ischemic stroke. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."

-

Nasdaq Stock Snapshot

DMAC Symbol

Nasdaq Market

-- Volume

-- Price

-- Change

Go to Detailed Stock Information ›

Upcoming Events

CKD3 Chronic Kidney Disease Drug Development

July 13 – July 15, 2020

View Events ›

Recent News

May 19, 2020 • 4:42 PM EDT

DiaMedica Therapeutics to Present at the 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020

May 13, 2020 • 4:41 PM EDT

DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study

May 13, 2020 • 4:40 PM EDT

DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study and Provides a Business Update and First Quarter 2020 Financial Results

Go to Press Releases ›